1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Podcast: FDA Panel Overwhelmingly Votes For Dexcom CGM to Replace Finger Sticks

The US FDA's Clinical Chemistry and Clinical Toxicology Devices Panel voted eight to two to recommend Dexcom's G5 Continuous Glucose Monitor to replace finger-stick testing in diabetic patients over the age of two. Also, a post-panel podcast chat with Dexcom's Steve Pacelli.

Event

The conference room erupted in applause July 21 as an FDA advisory panel overwhelmingly voted to recommend Dexcom's G5 Continuous Glucose Monitor system as a replacement, rather than simply an adjunct, to conventional finger-stick testing for diabetics. In an eight to two vote the Clinical Chemistry and Clinical Toxicology Devices Panel voted the benefits of the expanded indication outweigh the risks.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor

 
• By Shubham Singh

After switching production of coatings for its continuous glucose monitors in-house to improve supply, Dexcom ran afoul of US FDA for failing to submit a premarket notification. Firm says launch of 15-day sensor will not be delayed by the problems.

Research Finds Benefit From DME Suppliers For People Living With Diabetes

 
• By Elizabeth Orr

People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.

Dexcom Faces US FDA Warning Amid Agency Review Of 15-Day Sensor

 
• By Shubham Singh

Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.

Libre 3 Sensors: With Second Plant Online, Abbott Aims For Under-Penetrated ‘Intensive Insulin’ Segment

 
• By Shubham Singh

Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.

More from Device Area

Enovis Appoints Damien McDonald CEO, Reaffirms Q1 Guidance Amid Strategic Growth Push

 
• By Marion Webb

Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.

Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor

 
• By Shubham Singh

After switching production of coatings for its continuous glucose monitors in-house to improve supply, Dexcom ran afoul of US FDA for failing to submit a premarket notification. Firm says launch of 15-day sensor will not be delayed by the problems.